These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 36569926)

  • 1. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
    Kwon S
    Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK-STAT signaling pathway in non-infectious uveitis.
    Su Y; Tao T; Liu X; Su W
    Biochem Pharmacol; 2022 Oct; 204():115236. PubMed ID: 36041544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK/STAT as a Potential Therapeutic Target for Osteolytic Diseases.
    Godoi MA; Camilli AC; Gonzales KGA; Costa VB; Papathanasiou E; Leite FRM; Guimarães-Stabili MR
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
    Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
    Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
    Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
    Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.
    Zhao R; Hu Z; Zhang X; Huang S; Yu G; Wu Z; Yu W; Lu J; Ruan B
    Cell Commun Signal; 2024 Jan; 22(1):68. PubMed ID: 38273295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
    Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
    Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The regulation of JAKs in cytokine signaling and its breakdown in disease.
    Hammarén HM; Virtanen AT; Raivola J; Silvennoinen O
    Cytokine; 2019 Jun; 118():48-63. PubMed ID: 29685781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases.
    Gao Q; Liang X; Shaikh AS; Zang J; Xu W; Zhang Y
    Curr Drug Targets; 2018; 19(5):487-500. PubMed ID: 27928945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
    Kim HO
    Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
    Karati D; Mahadik KR; Trivedi P; Kumar D
    Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
    Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics and non-canonical aspects of JAK/STAT signalling.
    Mohr A; Chatain N; Domoszlai T; Rinis N; Sommerauer M; Vogt M; Müller-Newen G
    Eur J Cell Biol; 2012; 91(6-7):524-32. PubMed ID: 22018664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
    Huang IH; Chung WH; Wu PC; Chen CB
    Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
    Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
    Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK/STAT: Why choose a classical or an alternative pathway when you can have both?
    Puigdevall L; Michiels C; Stewardson C; Dumoutier L
    J Cell Mol Med; 2022 Apr; 26(7):1865-1875. PubMed ID: 35238133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of Janus kinase trans-activation.
    Caveney NA; Saxton RA; Waghray D; Glassman CR; Tsutsumi N; Hubbard SR; Garcia KC
    Cell Rep; 2023 Mar; 42(3):112201. PubMed ID: 36867534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Specific Roles of JAK/STAT Signaling Pathway in Sepsis.
    Cai B; Cai JP; Luo YL; Chen C; Zhang S
    Inflammation; 2015 Aug; 38(4):1599-608. PubMed ID: 25676437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.